Karil Bellah, MD
Cardiovascular Disease · Salina, KSNPI 1518921485
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 426 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 15.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,632 and has fallen 59.3% since, to $664 in 2025.
Across 426 payments — averaging $15.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- Medtronic$868
- Merck$735
- Johnson & Johnson$675
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$549
- Amgen$535
- plus $2K from 28 others
What the payments were for
- Food & beverage$6,723100%
- Education$210%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 84 | $1,028 |
| Medtronic(2 entities) | 59 | $868 |
| Merck | 47 | $735 |
| Johnson & Johnson | 46 | $675 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 34 | $549 |
| Amgen | 31 | $535 |
| AstraZeneca | 29 | $449 |
| Pfizer | 19 | $275 |
| Amarin Pharma, Inc. | 10 | $206 |
| Abbott | 3 | $167 |
| Bayer | 2 | $166 |
| Boehringer Ingelheim | 9 | $165 |
| E.r. Squibb & Sons, L.L.C. | 7 | $105 |
| Regeneron Healthcare Solutions, Inc. | 5 | $96 |
| Astellas Pharma US Inc | 3 | $66 |
| Sanofi-aventis U.S. LLC | 5 | $66 |
| Bardy Diagnostics, Inc. | 3 | $57 |
| Kestra Medical Technology Services, Inc. | 3 | $57 |
| Actelion Pharmaceuticals US, Inc. | 3 | $56 |
| Philips North America LLC | 2 | $51 |
| Boston Scientific | 3 | $51 |
| Abiomed | 2 | $49 |
| Gilead | 3 | $44 |
| Akcea Therapeutics, Inc. | 2 | $38 |
| Alnylam Pharmaceuticals Inc. | 2 | $33 |
| Amryt Pharma Holdings Ltd | 2 | $32 |
| Esperion Therapeutics, Inc. | 1 | $20 |
| W. L. Gore & Associates, Inc. | 1 | $18 |
| Infobionic, Inc | 1 | $17 |
| Cvrx, Inc. | 1 | $15 |
| Novo Nordisk | 1 | $14 |
| Lexicon Pharmaceuticals, Inc. | 1 | $14 |
| EKOS Corporation | 1 | $14 |
| Bracco Diagnostics Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$144
- CARDIOMEMS$120
- SYMPLICITY G3$119
How this compares
$6,744 in reported general payments places this provider in the 75th percentile of 175 cardiovascular disease providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 432 | $300,440 |
| EntrestoSacubitril/Valsartan | 316 | $263,237 |
| XareltoRivaroxaban | 151 | $115,502 |
| Repatha SureclickEvolocumab | 83 | $68,308 |
| JardianceEmpagliflozin | 70 | $49,999 |
| FarxigaDapagliflozin Propanediol | 66 | $35,076 |
| BrilintaTicagrelor | 41 | $20,758 |
| MultaqDronedarone Hcl | 20 | $14,656 |
| CorlanorIvabradine Hcl | 15 | $8,540 |
| Valsartan | 284 | $7,459 |
| Metoprolol Succinate | 443 | $6,038 |
| Ranolazine ErRanolazine | 59 | $4,903 |
| Digoxin | 233 | $4,087 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 111 | $3,055 |
| Diltiazem 24hr ErDiltiazem Hcl | 153 | $2,757 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $275 | $300,440432 claims |
| NovartisEntresto | $1,028 | $263,237316 claims |
| Johnson & JohnsonXarelto | $675 | $115,502151 claims |
| AstraZenecaFarxiga, Brilinta | $449 | $55,834107 claims |
| Boehringer IngelheimJardiance | $165 | $49,99970 claims |
| Sanofi-aventis U.S. LLCMultaq | $66 | $14,65620 claims |
| AmgenCorlanor | $535 | $8,54015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 175 cardiovascular disease providers in Kansas.
Other cardiovascular disease in Salina
- Bassem ChehabWichita$482K
- Vasvi SinghOverland Park$405K
- Joseph GalichiaWichita$177K
- Wassim ShaheenWichita$137K
- Layne ReusserWichita$91K
- Aziz MaksoudWichita$81K
- Mildred OpondoHays$59K
- Rachel SoslandOverland Park$33K
- Ahmed ElballatOverland Park$22K
- Timothy BeaverKansas City$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.